Antheia Adds $24 Million to Series C

<p><strong><span class&equals;"legendSpanClass">MENLO PARK<&sol;span><&sol;strong> &&num;8212&semi; <u><a href&equals;"https&colon;&sol;&sol;edge&period;prnewswire&period;com&sol;c&sol;link&sol;&quest;t&equals;0&amp&semi;l&equals;en&amp&semi;o&equals;4603325-1&amp&semi;h&equals;1802099239&amp&semi;u&equals;http&percnt;3A&percnt;2F&percnt;2Fantheia&period;bio&percnt;2F&amp&semi;a&equals;Antheia" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener">Antheia<&sol;a><&sol;u>&comma; an advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation&comma; has completed a second close of its Series C financing&comma; raising an additional &dollar;24 million&period; Combined with additional available capital and non-dilutive funding&comma; including multiple project agreements with the U&period;S&period; government&comma; the company has secured more than &dollar;175 million over the past year&period;<&sol;p>&NewLine;<p>Proceeds from the financing will be used to expand Antheia&&num;8217&semi;s commercial manufacturing capacity&comma; advance the company&&num;8217&semi;s vast pipeline of late-stage biosynthetic pharmaceutical ingredients to market&comma; and establish its U&period;S&period; manufacturing operations to support national onshoring priorities&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Advanced biosynthesis has immense potential to transform pharmaceutical supply chains and unlock a new era of innovative medicines&comma;&&num;8221&semi; said Dr&period; Christina Smolke&comma; CEO and co-founder of Antheia&period; &&num;8220&semi;Building on the success of our Series C&comma; this additional infusion of capital will fuel our efforts to address urgent supply chain vulnerabilities and more broadly&comma; lead a paradigm shift for pharmaceutical manufacturing&period;&&num;8221&semi;<&sol;p>&NewLine;<p>The second close was led by ATHOS KG and America&&num;8217&semi;s Frontier Fund&comma; with participation from several existing investors&comma; including Global Health Investment Corporation &lpar;GHIC&rpar;&comma; who co-led the <u><a href&equals;"https&colon;&sol;&sol;edge&period;prnewswire&period;com&sol;c&sol;link&sol;&quest;t&equals;0&amp&semi;l&equals;en&amp&semi;o&equals;4603325-1&amp&semi;h&equals;1508514038&amp&semi;u&equals;https&percnt;3A&percnt;2F&percnt;2Fantheia&period;bio&percnt;2Fantheia-raises-56-million-in-series-c-financing-to-fuel-global-commercialization-strategy&percnt;2F&amp&semi;a&equals;initial&plus;Series&plus;C&plus;close" target&equals;"&lowbar;blank" rel&equals;"nofollow noopener">initial Series C close<&sol;a><&sol;u> with EDBI&period;<&sol;p>&NewLine;<p>&&num;8220&semi;America&&num;8217&semi;s Frontier Fund invests in companies that strengthen U&period;S&period; industrial leadership and secure critical supply chains&comma;&&num;8221&semi; said Jeff Karras&comma; General Partner at America&&num;8217&semi;s Frontier Fund&period; &&num;8220&semi;Antheia is redefining how essential medicines are made by combining advanced biosynthesis with scalable domestic manufacturing&period; This approach addresses longstanding shortages&comma; long lead times&comma; and geopolitical risk&period; We are excited to support Antheia as it builds a more resilient and secure U&period;S&period; pharmaceutical ecosystem&period;&&num;8221&semi;<&sol;p>&NewLine;